STEVEN REYES: Open Payments
NPI 1144429366 · ST PETERSBURG, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$902 in 46 payments from 20 companies in 2025. Trend: 2023 $823 · 2024 $1,081 · 2025 $902
Food & beverage: $902
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $144 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $120 |
| Novo Nordisk Inc | 4 | $82 |
| PFIZER INC. | 4 | $79 |
| GlaxoSmithKline, LLC. | 4 | $70 |
| Abbott Laboratories | 2 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $39 |
| AstraZeneca Pharmaceuticals LP | 2 | $39 |
| GENZYME CORPORATION | 1 | $38 |
Products named: CAPLYTA, TRELEGY ELLIPTA, REXULTI, VRAYLAR, FREESTYLE LIBRE 2, Ozempic, Kerendia, AIRSUPRA.
Industry payments across FL — which companies pay providers there.
